Pathological mechanisms involved in diabetic neuropathy: Can we slow the process?

Current Opinion in Investigational Drugs

Volumn 7, Issue 4, 2006, Pages 324-337

  Sima, Anders A F ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetic neuropathy; Metabolic and molecular abnormalities; Pathological correlates; Type 1 diabetes; Type 2 diabetes

Indexed keywords

4 AMINOBUTYRIC ACID DERIVATIVE; ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; ALPHA TOCOPHEROL; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTILIPEMIC AGENT; ANTIOXIDANT; ASCORBIC ACID; C PEPTIDE; CAPSAICIN; GAMMA LINOLENIC ACID; INSULIN; LEVACECARNINE; LIPID; OPIATE; POLYOL; PRIMROSE OIL; THIOCTIC ACID;

ACUTE DISEASE; APOPTOSIS; CLINICAL PROTOCOL; CLINICAL TRIAL; DEGENERATIVE DISEASE; DIABETES CONTROL; DIABETIC NEUROPATHY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MODEL; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GENETIC REGULATION; HUMAN; HYPERGLYCEMIA; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; LIPID METABOLISM; METABOLIC DISORDER; NERVE FIBER DEGENERATION; NERVE FIBER REGENERATION; NEUROPATHIC PAIN; NEUROTROPISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PREVALENCE; PRIMARY PREVENTION; PROTEIN PROTEIN INTERACTION; REVIEW; RISK FACTOR; SPINAL GANGLION; SYMPTOM; UNSPECIFIED SIDE EFFECT;

ALDEHYDE REDUCTASE; ANIMALS; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; HUMANS; HYPERGLYCEMIA; LIPID METABOLISM; NERVE DEGENERATION; NERVE GROWTH FACTOR; OXIDATIVE STRESS; POLYMERS;

EID: 33645776476     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (180)

1. Sima AAF: Diabetic neuropathy: Pathogenetic backgrounds, current and future therapies. Expert Rev Neurotherapeutics (2001) 1(2):225-238.
2. Pfeifer MA, Schumer MP, Gelber DA: Aldose reductase inhibitors: The end of an era or the need for different trial designs? Diabetes (1997) 46(Suppl 2):S582-S589.
3. Ziegler D, Hanefeld M, Ruhnau K-J, Hasche H, Lobisch M, Schutte K, Kerum G, Malessa R, The ALADIN III Study Group: Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoid acid: A 7-month multicenter randomized controlled trial (ALADIN III Study). Diabetes Care (1999) 22(8):1296-1301.
4. Apfel SC, Kessler JA, Adomato BT, Litchy WJ, Sanders C, Rask CA: Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group. Neurology (1998) 51(3):695-702.
5. Sima AAF: Diabetic neuropathy in type 1 and type 2 diabetes and the effects of C-peptide. J Neurol Sci (2004) 220(1-2):133-136.
6. Sima AAF: New insights into the metabolic and molecular basis for diabetic neuropathy. Cell Mol Life Sci (2003) 60(11):2445-2464.
7. Sima AAF, Kamiya H: Diabetic neuropathy differs in type 1 and type 2 diabetes. Ann NY Acad Sci: in press.
8. Greene DA, Sima AAF, Pfeifer MA, Albers JW: Diabetic neuropathy. Annu Rev Med (1990) 41:303-317.
9. Sima AAF, Thomas PK, Ishii D, Vinik A: Diabetic neuropathies. Diabtologia (1997) 40(Suppl 3):B74-B77.
10. Thomas PK: Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. Diabetes (1997) 48(Suppl 2):S54-S57.
11. Vinik AI, Holland MT, Le Beau JM, Liuzzi FJ, Stansberry KB, Colen LB: Diabetic neuropathies. Diabetes Care (1992) 15(12):1926-1975.
12. Stief CG, Ziegler D: Urogenital system. In: Textbook of Diabetic Neuropathy. Gries FA, Cameron NE, Low PA, Ziegler D (Eds), Thieme Verlag, Stuttgart, Germany (2003):262-272.
13. Richards BW, Jones FR Jr, Younge BR: Causes and prognosis in 4,278 cases of paralyses of the oculomotor, trochlear and abducens nerves. Am J Ophthalmol (1992) 113(5):489-496.
14. Fraser DM, Campbell IW, Ewing DJ, Clarke BF: Mononeuropathy in diabetes mellitus. Diabetes (1979) 28(2):96-101.
15. Young MJ, Breddy JL, Veves A, Boulton AJM: The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study. Diabetes Care (1994) 17(6):557-560.
16. Fedele D, Comi G, Coscelli C, Cucinotta D, Feldman EL, Ghirlanda G, Greene DA, Negrin P, Santeusanio F: A multicenter study on the prevalence in diabetic neuropathy in Italy. Italian Diabetic Neuropathy Committee. Diabetes Care (1997) 20(5):836-843.
17. Wikblad K, Smide B, Bergström A, Kessi J, Mugusi F: Outcome of clinical foot examination in relation to self-perceived health and glycaemic control in a group of urban Tanzanian diabetic patients. Diabetes Res Clin Pract (1997) 37(3):185-192.
18. Adler AI, Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, Smith DG: Risk factors for diabetic peripheral sensory neuropathy. Results of the Seattle Prospective Diabetic Foot Study. Diabetes Care (1997) 20(7):1162-1167.
19. Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, Wilson DM, O'Brien PC, Melton LJ 3rd. Service FJ: The prevalence by staged severity of various types of diabetic neuropathy, retinopathy and nephropathy in a population based cohort: The Rochester Diabetic Neuropathy Study. Neurology (1993) 43(11):817-824.
20. Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, Nuber A, Pozza G, Ward JD: Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: The EURODIAB IDDM Complications Study. Diabetologia (1996) 39(11):1377-1384.
21. Melton LJ 3rd, Dyck PJ: Epidemiology. In: Diabetic Neuropathy. Dyck PJ, Thomas PK (Eds), WB Saunders Co, New York, NY, USA (1999):239-254.
22. Sima AAF: C-peptide and diabetic neuropathy. Expert Opin Invest Drugs (2003) 12(9):1471-1488.
23. Intensive blood-glucose control with sulphonylureas or insulin compared wtth conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet (1998) 352(9131):837-853.
24. Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M: Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med (1995) 333(2):89-94.
25. Tesfaye S, Chaturverdi N, Eaton SEM, Ward JD, Fuller JH: Cardiovascular risk factors predict the development of diabetic peripheral neuropathy. Diabetes (2000) 49(Suppl 1):A34.
26. Young RJ, Macintyre CCA, Martyn CN, Prescott RJ, Ewing DJ, Smith AF, Viberti G, Clarke BF: Progression of subclinical polyneuropathy in young patients with type 1 (insulin-dependent) diabetes: Associations with glycaemic control and microangiopathy (microvascular complications). Diabetologia (1986) 29(3):156-161.
27. Young RJ, Macintyre CCA, Ewing DJ, Prescott RJ: Prediction of neuropathy over 5 years in young insulin-dependent diabetic patients. Diabetic Med (1988) 5:7.
28. Report and recommendation of the San Antonio conference on diabetic neuropathy. Diabetes (1988) 37(7):1000-1004.
29. Proceedings of a consensus development conference on standardized measures in diabetic neuropathy. Clinical measures Neurology (1992) 42(9):1823-1829.
30. Dyck PJ, Davies JL, Litchy WJ, O'Brien PC: Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study Cohort. Neurology (1997) 49(1):229-239.
31. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA: A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care (1994) 17(11):1281-1289.
32. Brands AMA, Kesseto RPC, de Haan EHF, Kappelle LJ, Bessels GJ: Cerebral dysfunction in type 1 diabetes: Effects of insulin, vascular risk factors and blood-glucose levels. Br J Pharmacol (2004) 490(1-3):159-168.
33. Sima AAF, Kamiya H, Li ZG: Insulin, C-peptide, hyperglycemia, and central nervous system complications in diabetes. Eur J Pharmacol (2004) 490(1-3):187-197.
34. Li ZG, Zhang W, Sima AAF: The role of impaired insulin/IGF action in primary diabetic encephalopathy. Brain Res (2005) 1037(1-2):12-24.
35. Sima AAF, Nathaniel V, Bril V, McEwen TAJ, Greene DA: Histopathological heterogeneity of neuropathy in insulin-dependent and non-insulin-dependent diabetes, and demonstration of axoglial dysfunction in human diabetic neuropathy. J Clin Invest (1988) 81(2):349-364.
36. Sima AAF, Bril V, Greene DA: Pathogenetic heterogeneity in human diabetic neuropathy. Pediatr Adoles Endocrinol (1989) 18:56-62.
37. Sima AAF, Zhang W, Xu G, Sugimoto K, Guberski DL, Yorek MA: A comparison of diabetic polyneuropathy in type II diabetic BBZDR/Wor rats and in type I diabetic BB/Wor rats. Diabetologia (2000) 43(6):786-793.
38. Sima AAF: Diabetes underlies common neurological disorders. Ann Neurol (2004) 56(4):459-461.
39. Kamiya H, Murakawa Y, Zhang W, Sima AAF: Unmyelinated fiber sensory neuropathy differs in type 1 and type 2 diabetes. Diabetes Metabol Res Rev (2005) 21(5):448-58.
40. Sima AAF, Lattimer SA, Yagihashi S, Greene DA: 'Axo-glial dysjunction': A novel structural lesion that accounts for poorly reversible slowing of nerve conduction in the spontaneously diabetic bio-breeding rat. J Clin Invest (1986) 77(2):474-484.
41. Sima AAF, Zhang W, Li Z-G, Murakawa Y, Pierson CR: Molecular alterations underlie nodal and paranodal degeneration in type 1 diabetic neuropathy and are prevented by C-peptide. Diabetes (2004) 63(6):1556-1563.
42. Schmidt RE, Dorsey DA, Beaudet LN, Parvin CA, Zhang W, Sima AAF: Experimental rat models of types 1 and 2 diabetes differ in sympathetic neuronal dystrophy. J Neuropathol Exp Neurol (2004) 63(5):450-460.
43. Sima AAF, Prashar A, Nathaniel V, Bril V, Werb MR, Greene DA: Overt diabetic neuropathy: Repair of axo-glial dysjunction and axonal atrophy by aldose reductase inhibition and its correlation to improvement in nerve conduction velocity. Diabetic Med (1993) 10(2):115-121.
44. Sima AAF: Structural-functional interactions in the in the therapeutic response of diabetic neuropathy. J Diabetic Complicat (1992) 6(1):40-44.
45. Pierson CR, Zhang W, Murakawa Y, Sima AAF: Insulin deficiency rather than hyperglycemia accounts for impaired neurotrophic responses and nerve fiber regeneration in type 1 diabetic neuropathy. J Neuropathol Exp Neurol (2003) 62(3):260-271.
46. Yagihashi S, Sugimoto K, Wada R: Different neuropathic patterns between type 1 and type 2 animal models. In: Pathogenesis and Treatment of NIDDM and its Related Problems. Sakamoto N, Albert KG, Hotta N (Eds), Elsevier, Amsterdam, the Netherlands (1994):401-405.
47. Sugimoto K, Murakawa Y, Zhang W-X, Xu G, Sima AAF: Insulin receptor in rat peripheral nerve: Its localization and alternatively spliced isoforms. Diabetes Metabol Res Rev (2000) 16(5):354-363.
48. Sugimoto K, Murakawa Y, Sima AAF: Expression and localization of insulin receptor in rat dorsal root ganglion and spinal cord. J Peripheral Nerv Syst (2002) 7(1):44-53.
49. Brussee V, Cunningham FA, Zochodne DW: Direct insulin signaling of neurons reverses diabetic neuropathy. Diabetes (2004) 53(7):1824-1830.
50. Greene DA, Lattimer SA, Sima AAF: Sorbitol, phosphoinositides and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med (1987) 316(10):599-606.
51. Stevens MJ, Lattimer SA, Kamijo M, Van Huysen C, Sima AA, Greene DA: Osmotically-induced nerve taurine depletion and the compatible osmolyte hypothesis in experimental diabetic neuropathy in the rat. Diabetologia (1993) 36(7):608-614.
52. Aruoma OI, Halliwell B, Hoey BM, Butler J: The antioxidant action of taurine, hypotaurine and their metabolic precursors. Biochem J (1968) 256(1):251-255.
53. El Idrissi A, Trenkner E: Growth factors and taurine protect against excitotoxicity by stabilizing calcium homeostasis and energy metabolism. J Neurosci (1999) 19(21):9459-9466.
54. Greene DA, Sima AAF, Stevens MJ, Feldman EL, Killen PD, Henry DN, Thomas T, Dananberg J, Lattimer SA: Aldose reductase inhibitors: An approach to the treatment of diabetic nerve damage. Diabetes Metab Rev (1993) 9(3):189-217.
55. Sugimoto K, Murakawa Y, Sima AAF: Diabetic neuropathy - a continuing enigma. Diabetes Metabol Res Rev (2000) 16(6):408-433.
56. Judzewitsch RG, Jaspan JB, Polonsky KS, Weinberg CR, Halter JB, Halar E, Pfeifer MA, Vukadinovic C, Bernstein L, Schneider M, Liang KY et al: Aldose reductase inhibition improves nerve conduction velocity in diabetic patients. N Engl J Med (1983) 308(3):119-125.
57. Lewin IG, O'Brien IAD, Morgan MH, Corrall RJM: Clinical and neurophysiological studies with the aldose reductase inhibitor, sorbinil, in symptomatic diabetic neuropathy. Diabetologia (1964) 26(6):445-448.
58. Macleod AF, Boutton AJM, Owens DR, Van Rooy P, Van Gerven JM, Macrury S, Scarpello JH, Segers O, Heller SR, Van Der Veen EA: A multicentre trial of the aldose-reductase inhibitor tolrestat in patients with symptomatic diabetic peripheral neuropathy. North European Tolrestat Study Group. Diabetes Metab (1992) 18(1):14-20.
59. Krentz AJ, Honigsberger L, Ellis SH, Hardman M, Nattrass M: A 12-month randomized controlled study of the aldose reductase inhibitor ponalrestat in patients with chronic symptomatic diabetic neuropathy. Diabetic Med (1992) 9(5):463-468.
60. Sima AAF, Greene DA, Brown MB, Hodman TC, Hicks D, Graepel GJ, Bochenek WJ, Beg M, Gonen B: Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group. J Diabetes Complicat (1993) 7(3):157-169.
61. Sima AAF, Nathaniel V, Prashar A, Bril V, Greene DA: Endoneurial microvessels in human diabetic neuropathy: Endothelial cell dysjunction and lack of treatment effect by aldose reductase inhibitor. Diabetes (1991) 40(9):1090-1099.
62. Sima AAF, Bril V, Nathaniel V, McEwen TAJ, Brown MB, Lattimer SA, Greene DA: Regeneration and repair of myelinated fibers in sural-nerve biopsy from patients with diabetic neuropathy treated with sorbinil. N Eng J Med (1988) 319(9):548-555.
63. Laudadio C, Sima AAF: Design of controlled clinical trials for diabetic polyneuropathy. Semin Neurol (1996) 16(2):187-191.
64. Laudadio C, Sima AAF: Progression rates of diabetic neuropathy in placebo patients in an 18-month clinical trial. Ponalrestat Study Group. J Diabetes Complicat (1998) 12(3):121-127.
65. Heesom AE, Millward A, Demaine AG: Susceptibility to diabetic neuropathy in patients with insulin dependent diabetes mellitus is associated with a polymorphism at the 5′ end of the aldose reductase gene. J Neurol Neurosurg Psychiatry (1988) 64(2):213-216.
66. Heesom AE, Hibberd ML, Millward A, Demaine AG: Polymorphism in the 5′-end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type I diabetes. Diabetes (1997) 46(2):287-291.
67. Oates PJ, Mylari BL: Aldose reductase inhibitors: Therapeutic implications for diabetic complications. Expert Opin Invest Drugs (1999) 8(12):2095-2119.
68. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature (2001) 414(6865):813-820.
69. Schmeichel AM, Schmelzer JD, Low PA: Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. Diabetes (2003) 52(1):165-171.
70. Baynes JW, Thorpe SR: Role of oxidative stress in diabetic complications: A new perspective on an old paradigm. Diabetes (1999) 48(1):1-9.
71. Baynes JW: Role of oxidative stress in development of complications in diabetes. Diabetes (1991) 40(4):405-412.
72. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, Nyengaard JR, van den Enden M, Kilo C, Tilton RG: Hyperglycemic pseudohypoxia and diabetic complications. Diabetes (1993) 42(6):801-813.
73. Yoshida K, Hirokawa J, Tagami S, Kawakami Y, Urata Y, Kondo T: Weakened cellular scavenging activity against oxidative stress in diabetes mellitus: Regulation of glutathione synthesis and efflux. Diabetologia (1995) 38(2):201-210.
74. Vlassara H, Brownlee M, Cerami A: Nonenzymatic glycosylation of peripheral nerve protein in diabetes mellitus. Proc Natl Acad Sci USA (1981) 78(8):5190-5192.
75. Soulis-Liparota T, Cooper ME, Dunlop M, Jermus G: The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia (1995) 38(4):387-394.
76. Takagi Y, Kashiwagi A, Tanaka Y, Asahina T, Kikkawa R, Shigeta Y: Significance of fructose-induced protein oxidation and formation of advanced glycation end product. J Diabetes Complicat (1995) 9(2):87-91.
77. McCord JM: Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med (1985) 312(3):159-163.
78. Hunt JV, Wolff SP: Oxidative glycation and free radical production: A causal mechanism of diabetic complications. Free Radic Res Commun (1991) 12-13(1):115-123.
79. Hunt JV, Dean RT, Wolff SP: Hydroxyl radical production and autoxidative glycatlon. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing. Biochem J (1988) 256(1):205-212.
80. Cameron NE, Cotter MA: Neurovascular dysfunction in diabetic rats. Potential contribution of autoxidation and free radicats examined using transition metal chelating agents. J Clin Invest (1995) 96(2):1159-1163.
81. Bierhaus A, Chevion S, Chevion M, Hofmann M, Quehenberger P, Illmer T, Luther T, Berentshtein E, Tritschler H, Muller M, Wahl P et al: Advanced glycation end product-induced activation of NF-κB is suppressed by α-lipoic acid in cultured endothelial cells. Diabetes (1997) 46(9):1481-1490.
82. Wautier JL, Zoukourian C, Chappey O, Wautier MP, Guillausseau PJ, Cao R, Hori O, Stern D, Schmidt AM: Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeabillty in diabetic rats. J Clin Invest (1996) 97(1):238-243.
83. Lipinski B: Pathophysiology of oxidative stress in diabetes mellitus. J Diabetes Complicat (2001) 15(4):203-210.
84. Ziegler D, Reljanovi M, Meknert H, Gries FA: α-Lipoic acid in the treatment of diabetic polyneuropathy in Germany: Current evidence from clinical trials. Exp Clin Endocrinol Diabetes (1999) 107(7):421-430.
85. Cameron NE, Cotter MA: Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes (1997) 46(Suppl 2):S31-S37.
86. Cameron NE, Cotter MA: Oxidative stress and abnormal lipid metabolism in diabetic complications. In: Chronic Complication in Diabetes. Sima AAF (Ed), Harwood Academic Publishers, Amsterdam, the Netherlands (1999):97-130.
87. Stevens MJ, Zhang W, Li F, Sima AAF: C-peptide corrects endoneurial blood flow but not oxidative stress in type 1 BB/Wor rats. Am J Physiol Endocrinol Metab (2004) 287(3):E497-E505.
88. Kamiya H, Zhang W, Sima AAF: C-peptide prevents nociceptive sensory neuropathy in type 1 diabetes. Ann Neurol (2004) 56(6):827-835.
89. Sima AAF, Zhang W, Sugimoto K, Henry D, Li Z-G, Wahren J, Grunberger G: C-peptide prevents and improves chronic type 1 diabetic neuropathy in the BB/Wor rat. Diabetologia (2001) 44(7):889-897.
90. Vinik A, Pittenger G, Stausberry K, Park TS, Erbos T, Skeen M: Neurotrophic factors. In: Textbook of Diabetic Neuropathy. Gries FA, Cameron NE, Low PA, Ziegler D (Eds), Thieme Verlag, Stuttgart, Germany (2003):129-144.
91. Sima AAF, Zhang W, Li ZG: Different apoptotic pathways are involved in primary hippocampal apoptosis in type 1 and type 2 diabetes. Annual Meeting of the Diabetic Neuropathy Study Group of the EASD (NEURODIAB), Regensburg, Germany (2004) 13:Abs 214.
92. Pierson CR, Zhang W, Murakawa Y, Sima AAF: Early gene responses of trophic factors in nerve regeneration differ in type 1 and type 2 diabetic polyneuropathies. J Neuropathol Exp Neurol (2002) 61(10):857-871.
93. Ebendal T: Function and evolution in the NGF family and its receptors. J Neurosci Res (1992) 32(4):461-470.
94. Brewster WJ, Fernyhough P, Diemel LT, Mohiuddin L, Tomlinson DR: Diabetic neuropathy, nerve growth factor and other neurotrophic factors. Trends Neurosci (1994) 17(8):321-325.
95. Tomlinson DR, Fernyhough P: Neurotrophism in diabetic neuropathy. In: Chronic Complications in Diabetes. Sima AAF (Ed), Harwood Academic Publishers, Amsterdam, the Netherlands (1999):167-182
96. Jakobsen J, Brimijoin S, Skan K, Sidenius P, Wells D: Retrograde axonal transport of transmitter enzymes, fucose-labeled protein, and nerve growth factor in streptozotocin-diabetic rats. Diabetes (1981) 30(10):797-803.
97. Hellweg R, Hartung HD: Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: A possible role for NGF in the pathogenesis of diabetic neuropathy. J Neurosci Res (1990) 26(2):258-267.
98. Apfel SC, Arezzo JC, Brownlee M, Federoff H, Kessler JA: Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res (1994) 634(1):7-12.
99. Diemel LT, Brewster WJ, Fernyhough P, Tomlinson DR: Expression of neuropeptides in experimental diabetes: Effects of treatment with nerve growth factor or brain-derived neurotrophic factor. Brain Res Mol Brain Res (1994) 21(1-2):171-175.
100. Hory-Lee F, Russell M, Lindsay RM, Frank E: Neurotrophin 3 supports the survival of developing muscle sensory neurons in culture. Prox Natl Acad Sci USA (1993) 90(7):2613-2617.
101. Emfors P, Lee KF, Kucera J, Jaenisch R: Lack of neurotrophin-3 leads to deficiencies in the peripheral nervous system and loss of limb proprioceptive afferents. Cell (1994) 77(4):503-512.
102. Sima AAF: Special issue: Trophic factors and inflammatory mediators in diabetic complications. Exp Diab Res (2003) 4(4):203-312.
103. Apfel SC: Neurotrophic factors in the therapy of diabetic neuropathy. Am J Med (1999) 107(2B):345-425.
104. Ishii DN, Guertin DM, Whalen LR: Reduced insulin-like growth factor-1 mRNA content in liver adrenal glands and spinal cord of diabetic rats. Diabetologia (1994) 37(11):1073-1081.
105. Wuarin L, Guertin DM, Ishii DN: Early reduction in insulin-like growth factor gene expression in diabetic nerve. Exp Neurol (1994) 130(1):106-114.
106. Sima AAF, Li Z-G, Zhang W: The insulin-like growth factor system and neurological complications in diabetes. Exp Diabesity Res (2003) 4(4):235-256.
107. Crosby SR, Tsigos C, Anderton CD, Gordon C, Young RJ, White A: Elevated plasma insulin-like growth factor binding protein-1 levels in type 1 (insulin-dependent) diabetic patients with peripheral neuropathy. Diabetologia (1992) 35(9):868-872.
108. Murphy LJ: The role of the insulin-like growth factors and their binding proteins in glucose homeostasis. Exp Diabesity Res (2003) 4(4):213-224.
109. Zhuang HX, Wuarin L, Fei ZJ, Ishii DN: Insulin-like growth factor (IGF) gene expression is reduced in neural tissues and liver from rats with insulin-dependent diabetes mellitus, and IGF treatment ameliorates diabetic neuropathy. J Pharmacol Exp Ther (1997) 283(1):366-374.
110. Xu G, Sima AAF: Altered immediate early gene expression is impaired in diabetic nerve: Implications in regeneration. J Nauropathol Exp Neurol (2001) 60(10):972-983.
111. Russell JW, Sullivan KA, Windebank AJ, Herrmann DN, Feldman EL: Neurons undergo apoptosis in animal and cell culture models of diabetes. Neurobiol Dis (1999) 6(5):347-363.
112. Reico-Pinto E, Rechler MM, Ishii DN: Effects of insulin, isulin-like growth factor II, and nerve growth factor on neurite formation and survival in cultured sympathetic and sensory neurons. J Neurosci (1988) 6(5):1211-1219.
113. Wang C, Li Y, Wible B, Angelides KJ, Ishii DN: Effects of insulin and insulin-like growth factors on neurofilament mRNA and tubulin mRNA content in human neuroblastoma SH-SY5Y cells. Brain Res Mol Brain Res (1992) 13(4):289-300.
114. Fernyhough P, Mill JF, Roberts JL, Ishii DN: Stabilization of tubulin mRNAs by insulin and insulin-like growth factor I during neurite formation. Brain Res Mol Brain Res (1989) 6(2-3):109-120.
115. Pierson CR, Zhang W, Sima AAF: Proinsulin C-peptide replacement in type 1 diabetic BB/Wor rats prevents deficits in nerve fiber regeneration. J Neuropathol Exp Neurol (2003) 62(7):765-779.
116. Li Z-G, Zhang W, Sima AAF: C-peptide enhances insulin-mediated cell growth and protection against high glucose-induced apoptosis in SH-SY5Y cells. Diabetes Metabol Res Rev (2003) 19(5):375-385.
117. Singhal A, Cheng C, Sun H, Zochodne DW: Near nerve local insulin prevents conduction slowing in experimental diabetes. Brain Res (1997) 763(2):209-214.
118. Grunberger G, Qiang X, Li Z, Mathews ST, Sbrissa D, Shisheva A, Sima AAF: Molecular basis for the insulinomimetic effecs of C-peptide. Diabetologia (2001) 44(10):1247-1257.
119. Grunberger G, Sima AAF: The C-peptide signaling. Exp Diabesity Res (2004) 5(1):25-36.
120. Kitamura T, Kimura K, Jung BD, Makondo K, Sakane N, Yoshida T, Saito M: Proinsulin C-peptide activates cAMP response element-binding proteins through the p38 mitogen-activated protein kinase pathway in mouse lung capillary andothelial cells. Biochem J (2002) 366(3):737-744.
121. Kitamura T, Kimura K, Makondo K, Furuya DT, Suzuki M, Yoshida T, Saito M: Proinsulin C-peptide increases nitric oxide production by enhancing mitogen-activated protein-kinase-dependent transcription of endothelial nitric oxide synthase in aortic endothelial cells of Wistar rats. Diabetologia (2003) 46(12):1698-1705.
122. Zhang W, Yorek M, Pierson CR, Murakawa Y, Breidenbach A, Sima AAF: Human C-peptide dose dependently prevents early neuropathy in the BB/Wor rat. Int J Exp Diabetes Res (2001) 2(3):187-193.
123. Sima AAF, Kamiya H: Insulin, C-peptide and diabetic neuropathy. Sci Med (2004) 10:308-319.
124. Li Z-G, Zhang W, Sima AAF: C-peptide prevents hippocampal apoptosis in type 1 diabetes. Int J Exp Diabetes Res (2002) 3(4):241-246.
125. Ekberg K, Brismar T, Johansson B-L, Jonsson B, Lindstrom P, Wahren J: Amelioration of sensory nerve dysfunction by C-peptide in patients with type 1 diabetes. Diabetes (2003) 52(2):536-541.
126. Johansson BL, Borg K, Fernqvist-Forbes E, Odergren T, Remahl S, Wahren J: C-peptide improves autonomic nerve function in IDDM patients. Diabetologia (1996) 39(6):687-895.
127. Johansson B-L, Borg K, Fernqvist-Forbes E, Kernell A, Odergren T, Wahren J: Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with type 1 diabetes mellitus. Diabetic Med (2000) 17(3):181-189.
128. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med (1993) 329(14):977-986.
129. +)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. J Clin Invest (1994) 94(2):853-859.
130. Stevens MJ, Lattimer SA, Feldman EL, Helton ED, Millington DS, Sima AA, Greene DA: Acetyl-L-carnitine deficiency as a cause of altered nerve myo-inositol content, Na,K-ATPase activity, and motor conduction velocity in the streptozotocin-diabetic rat. Metabolism (1996) 45(7):865-872.
131. Sima AAF, Ristic H, Merry A, Kamijo M, Lattimer SA, Stevens MJ, Greene DA: Primary preventive and secondary interventionary effects of acetyl-L-carnitine on diabetic neuropathy in the bio-breeding rat. J Clin Invest (1996) 97(8):1900-1907.
132. Horrobin DF: Essential fatty acids in the management of impaired nerve function in diabetes. Diabetes (1997) 46(Suppl 2):S90-S93.
133. Cameron NE, Cotter MA, Robertson S: Essential fatty acid diet supplementatlon. Effects on peripheral nerve and skeletal muscle function and capillarizatlon in streptozocin-induced diabetic rats. Diabetes (1991) 40(5):532-539.
134. Cameron NE, Cotter MA, Dines KC, Robertson S, Cox D: The effects of evening primrose oil on nerve function and capillarization in streptozotocin-diabetic rate: Modulalation by the cyclo-oxygenase inhibitor flurbiprofen. Br J Pharmacol (1993) 109(4):972-979.
135. Hotta N, Koh N, Sakakibara F, Nakamura J, Hamada Y, Hara T, Mori K, Nakashima E, Naruse K, Fukasawa H, Kakuta H, Sakamoto N: Effects of beraprost sodium and insulin on the electroretinogram, nerve conduction, and nerve blood flow in rats with streptozotocin-induced diabetes. Diabetes (1996) 45(3):361-366.
136. Chrast R, Verheijen MHG, Burrola P, Zhang W, Sima AAF, Lemke G: The Involvement of SREBP-1C and associated lipid metabolism in diabetic neuropathy. Society for Neuroscience (2004) 34:Abs 344.
137. Jensen ME, Messina EJ: C-peptide induces a concentration-dependent dilatation of skeletal muscle arterioles only in the presence of insulin. Am J Physiol (1999) 276(4 Pt 2):H1223+H1228.
138. +-ATPase activity in diabetes mellitus type I. Clin Sci (2000) 98(3):283-290.
139. Brismar T, Sima AAF: Changes in nodal function in nerve fibres of the spontaneously diabetic BB-Wistar rat: Potential clamp analysis. Acta Physiol Scand (1981) 113(4):499-506.
140. Sima AAF, Brismar T: Reversible diabetic nerve dysfunction: Structural correlates to electrophysiological abnormalities. Ann Neurol (1985) 18(1):21-29.
141. Thomas PK, Beamish NG, Small JR, King RH, Tesfaye S, Ward JD, Tsigos C, Young RJ, Boulton AJ: Paranodal structure in diabetic sensory polyneuropathy. Acta Neuropathol (1996) 92(6):614-620.
142. Giannini C, Dyck PJ: Axoglial dysfunction: A critical appraisal of definition, techniques and previous results. Microsc Res Tech (1996) 34(5):436-444.
143. Dyck PJ, Giannini C: Pathologic alterations in the diabetic neuropathies of humans: A review. J Neuropathol Exp Neurol (1996) 55(12):1181-1193.
144. Sima AAF: Diabetic polyneuropathy. J Neuropathol Exp Neurol (1997) 56(4):458.
145. Brown AA, Xu T, Arroyo EJ, Levinson SR, Brophy PJ, Peles E, Scherer SS: Molecular organization of the nodal region is not altered in spontaneously diabetic BB-Wistar rats. J Neurosci Res (2001) 65(2):139-149.
146. Sima AAF, Pierson CR: Diabetic neuropathy: A heterogeneous, dynamic and progressive disorder. J Neurosci Res (2001) 66(6):1226-1227.
147. Yamamoto K, Merry A, Sima AAF: An orderly development of paranodal axoglial junctions and bracelets of Nageotte in the rat sural nerve. Brain Res Dev Brain Res (1996) 96(1-2):36-45.
148. Brismar T, Sima AAF, Greene DA: Reversible and irreversible nodal dysfunction in diabetic neuropathy. Ann Neurol (1987) 21(5):504-507.
149. Cherian PV, Kamijo M, Angelides KJ, Sima AAF: Nodal Na+-channel displacement is associated with nerve conduction slowing in the chronically diabetic BB/W rat: Prevention by aldose reductase inhibition. J Diabetes Complicat (1996) 10(4):192-200.
150. Quattrini C, Tesfaye S: Understanding the impact of painful diabetic neuropathy. Diabetes Metabol Res Rev (2003) 19(Suppl 1):S2-S8.
151. Kapur D: Neuropathic pain and diabetes. Diabetes Metabol Res Rev (2003) 19(Suppl 1):S9-315.
152. Burchiel KJ, Russell LC, Lee RP, Sima AAF: Spontaneous activity of primary afferent neurons in diabetic BB Wistar rats. A possible mechanism of chronic diabetic neuropathic pain. Diabetes (1985) 34(11):1210-1213.
153. Chen X, Levine JD: Altered temporal pattern of mechanically evoked C-fiber activity in a model of diabetic neuropathy in the rat. Neuroscience (2003) 121(4):1007-1015.
154. Woolf CJ, Shorthand P, Reynolds M, Ridings J, Doubell T, Coggeshall RE: Reorganization of central terminate of myelinated primary afferents in rat dorsal horn following peripheral axotomy. J Comp Neurol (1995) 360(1):121-134.
155. Singleton JR, Smith AG, Bromberg MB: Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care (2001) 24(8):1448-1453.
156. Murakawa Y, Zhang W, Pierson CR, Brismar T, Ostenson CG, Efendic S, Sima AA: Impaired glucose tolerance and insulinopenia in the GK-rat causes peripheral neuropathy. Diabetes Metabol Res Rev (2002) 18(6):473-483.
157. Hong S, Morrow TJ, Paulson PE, Isom LL, Wiley JW: Early painful diabetic neuropathy is associated with differential changes of tetrodotoxin-sensitive and -resistant sodium channels in dorsal root ganglion neurons in the rat. J Biol Chem (2004) 279(28):29341-29350.
158. Hong S, Wiley JW: Early painful diabetic neuropathy is associated with differential changes in the expression and function of vanilloid receptor 1. J Biol Chem (2005) 280(1):618-627.
159. McQuay H, Carroll D, Jadad AR, Wiffen P, Moore A: Anticonvusant drugs for management of pain: A systematic review. Br Med J (1995) 311(7012):1047-1052.
160. McQuay HJ, Tramer M, Nye BA, Carroll D, Wiffen PJ, Moore PA: A systematic review of antidepressants in neuropathic pain. Pain (1996) 68(2-3):217-227.
161. Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J: Controlled-release oxycodone relieves neuropathic pain: A randomized controlled trial in painful diabetic neuropathy. Pain (2003) 108(1-2):71-78.
162. Sindrup SH, Andersen G, Madsen C, Smith T, Brosen K, Jensen TS: Tramadol relieves pain and allodynia in polyneuropathy: A randomized, double-blind, controlled trial. Pain (1999) 83(1):85-90.
163. Zhang WV, Li Wan Po A: The effictiveness of topically applied capsaicin. A meta-analysis. Eur J Clin Pharmacol (1994) 46(6):517-522.
164. Lesser H, Sharma U, LaMoreaux L, Poole RM: Pregabalin relieves symptoms of painful diabetic neuropathy: A randomized controlled trial. Neurology (2004) 63(11):2104-2010.
165. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U: Pregabalin for the treatment of painful diabetic neuropathy: A double-blind placebo-controlled trial. Pain (2004) 110(3):628-638.
166. Dworkin RH, Corbin AE, Young JP Jr, Sharma U, LaMoreaux L, Bockbrader H, Garofalo EA, Poole RM: Pregabalin for the treatment of
167. +-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett (2000) 280(2):107-110.
168. 3H] norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther (2000) 295(3):1086-1093.
169. ++ influx by gabapentin and pregabalin in the human neocortex. Nauropharmacology (2002) 42(2):229-236.
170. 3H] glutamate from rat caudial trigeminal nucleus slices. Pain (2001) 93(2):191-196.
171. Sima AAF, Calvani M, Mehra M, Amato A: Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: An analysis of two randomized, placebo-controlled trials. Diabetes Care (2005) 28(1):89-94.
172. Feldman EL, Sullivan KA, Kim B, Russell JW: Insulin-like growth factors regulate neuronal differentiation and survival. Neurobiol Dis (1997) 4(3-4):201-214.
173. Russell JW, Sullivan KA, Windebank AJ, Hermann DN, Feldman EL: Neurons undergo apoptosis in animal and cell culture models of diabetes. Neurobiol Dis (1999) 6(5):347-363.
174. Srinivasan S, Stevens M, Wiley JW: Diabetic peripheral neuropathy: Evidence for apoptosis and associated mitochondrial dysfunction. Diabetes (2000) 49(11):1932-1938.
175. Schmeichl AM, Schmelzer JD, Low PA: Oxidative Injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. Diabetes (2003) 52(1):165-171.
176. Cheng C, Zochodne DW: Sensory neurons with activated caspase-3 survive long-term experimental diabetes. Diabetes (2003) 52(9):2363-2371.
177. Wagstaff MJD, Collago-Moraes Y, Smith J, de Belleroche JS, Coffin RS, Latchman DS: Protection of neuronal cells from apoptosis by Hsp27 delivered with a herpes simplex virus-based vector. J Biol Chem (1999) 274(8):5061-5069.
178. Lewis SE, Mannion RJ, White FA, Coggeshall RE, Beggs S, Costigan M, Martin JL, Dillmann WH, Woolf CJ: A role for Hsp27 in sensory neuron survival. J Neurosci (1999) 19(20):8945-8953.
179. Li Z, Zhang W, Sima AAF: Different apoptotic pathways are involved in primary hippocampal apoptosis in type 1 and type 2 diabetes. Diabetes (2004) 53(Suppl 2):Abs 212.
180. Sima AAF, Zhang W, Li ZG: C-peptide replacement has a beneficial effect on CNS complications in type I diabetic BB/Wor rats. Annual Meeting of the Diabetic Neuropathy Study Group of the EASD (NEURODIAB), Regensburg, Germany (2004) 13:207.